Table 2.
Clinical Assessments in the Patient Group
| Overall | Missing (%) | |
|---|---|---|
| n | 20 | |
| MDS-UPDRS I (mean [SD]) | 12.35 (4.65) | 0 |
| MDS-UPDRS II (mean [SD]) | 12.60 (3.70) | 0 |
| MDS-UPDRS III (mean [SD]) | 20.00 (7.52) | 0 |
| MDS-UPDRS IV (mean [SD]) | 6.85 (2.68) | 0 |
| MDS-UPDRS total (mean [SD]) | 51.80 (11.80) | 0 |
| Hoehn & Yahr Stage (mean [SD]) | 2.05 (0.43) | 0 |
| disease duration (mean [SD]) | 9.44 (4.20) | 10 |
| levodopa eq dose (mean [SD]) | 1090.28 (375.06) | 10 |
Parkinson’s symptoms were assessed using the Unified Parkinson’s Disease Rating Scale of the International Parkinson and Movement Disorders Society (MDS-UPDRS, in therapeutic ON conditions), disease staging was performed using the modified Hoehn and Yahr Scale, disease duration was assessed as years since diagnosis, medication given as Levodopa-equivalent daily dose.